Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gut health boost could slow kidney disease, new trial hopes

NCT ID NCT07182942

Disease control Sponsor: Chujin Cao Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests whether a drug called Xiqing, which absorbs waste in the gut, works better when combined with probiotics in people with chronic kidney disease (CKD). The trial will enroll 120 adults with moderate to advanced CKD who are not on dialysis. Researchers will track kidney function and heart health to see if the combination helps slow disease progression.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Xiqing (a coated aldehyde oxystarch capsule that absorbs waste) and probiotics (Lactobacillus casei Zhang)
What this could lead to
If successful, this could show that combining Xiqing with probiotics better slows kidney disease progression and reduces complications.
What could go wrong
This is a small, early-phase trial with 120 participants, so results may not apply to all CKD patients. Risks include side effects from the drugs or no added benefit from probiotics.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2024

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Written informed consent was obtained; 2. ranging in age from 18 to 75 years; 3. CKD stage 3-5, that is, eGFR \< 60 mL/min/1.73 m2 with non-dialysis stage, no dialysis indication, temporarily stable condition and drug control stage; 4. tolerance of Xiqing and probiotics treatment. Exclusion Criteria: 1. with severe active infection, influence of nutritional status in patients with malignant tumor and other diseases; 2. patients during pregnancy or lactation; 3. unstable vital signs, the condition is not stable, need dialysis patients; 4. patients with intolerance of Xiqing; 5. patients with intolerance of probiotics; 6. taking corticosteroids, antibiotics or other immunosuppressive agents within the past 3 months; 7. taking adsorbent drugs, such as medicinal charcoal tablets, within the past 3 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CKD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CKD Drug effect

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    RECRUITING

    Wuhan, Hubei, 430030, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.